SavedAdd your journal

Journals / The Anatolian Journal of Cardiology / 2018 / Cilt: 19 - Sayı: 2

Relation between high serum hepcidin-25 level and subclinical atherosclerosis and cardiovascular mortality in hemodialysis patients

Özlem YAYAR
BARIŞ ESER
HARUN KILIÇ
Pages
117–122
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Linear regressionanalysis showed a positive correlation between CIMT and SH-25 in the study population and in those who died from CVD (r=0.41; p<0.05 andr=0.606; p<0.05, respectively).Conclusion: This study suggests that hepcidin is effective in cardiovascular mortality and pathophysiology of subclinical atherosclerosis in HDpatients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In hemodialysis (HD) patients, cardiovascular disease (CVD) is the major cause of mortality and morbidity.
📊
Key Findings & Data:Therefore, this study aims to investigate the relation of serum hepcidin-25 (SH-25) and sub-clinic atherosclerosismeasured by carotid intima-media thickness (CIMT) and mortality in HD patients.Methods: We enrolled 82 HD patients in a cross-control study.
💡
Conclusion & Impact:Linear regressionanalysis showed a positive correlation between CIMT and SH-25 in the study population and in those who died from CVD (r=0.41; p<0.05 andr=0.606; p<0.05, respectively).Conclusion: This study suggests that hepcidin is effective in cardiovascular mortality and pathophysiology of subclinical atherosclerosis in HDpatients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: In hemodialysis (HD) patients, cardiovascular disease (CVD) is the major cause of mortality and morbidity. In atherosclerotic diseases,iron gets accumulated in the arterial wall. Hepcidin is an important hormone in iron metabolism. Furthermore, hepcidin is associatedwith atherosclerotic disease. Therefore, this study aims to investigate the relation of serum hepcidin-25 (SH-25) and sub-clinic atherosclerosismeasured by carotid intima-media thickness (CIMT) and mortality in HD patients.Methods: We enrolled 82 HD patients in a cross-control study. We measured SH-25 using ELISA kit and CIMT using high-resolution real-time ultrasonography.After 4 years of first assessment, we investigated the relation between all-cause and cardiovascular mortality and SH-25 and CIMT.Results: Two patients were excluded because of renal transplantation. The survivors were younger (53.7±15.1 vs. 65.2±15.5; p<0.05) and CIMTwas lower (0.83±0.2 vs. 0.95±0.2; p<0.05); however, there was no significant difference in SH-25 levels between the groups (29.1±13 vs. 32.4±22.4;p=0.767). The patients who died of CVD were significantly older (63.7±16.1 vs. 53.7±15.1; p<0.05) and had significantly higher CIMT (0.94±0.2 vs.83±0.2; p<0.05). The SH-25 levels were statistically significantly higher in patients who died of CVD (40.3±25 vs. 29.1±13; p<0.05). Linear regressionanalysis showed a positive correlation between CIMT and SH-25 in the study population and in those who died from CVD (r=0.41; p<0.05 andr=0.606; p<0.05, respectively).Conclusion: This study suggests that hepcidin is effective in cardiovascular mortality and pathophysiology of subclinical atherosclerosis in HDpatients.

🔖

Cite This Article

YAYAR, Ö., ESER, B., KILIÇ, H. (2018). Relation between high serum hepcidin-25 level and subclinical atherosclerosis and cardiovascular mortality in hemodialysis patients. The Anatolian Journal of Cardiology, Cilt: 19 - Sayı: 2, 117–122. https://ajindex.com/articles/365240

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta 2009; 1790: 718-23. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood). 2007; 232: 1014-20.
  2. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009; 22: 70-7.
  3. Mostovaya IM, Bots ML, van den Dorpel MA, Goldschmeding R, den Hoedt CH, Kamp O, et al. Left ventricular mass in dialysis patients, determinants and relation with outcome. Results from the COnvectiveTRansportSTudy (CONTRAST). PLoS One 2014; 9: e84587. Hsieh YP, Huang CH, Lee CY, Chen HL, Lin CY, Chang CC. Hepcidin-25 negatively predicts left ventricular mass index in chronic kidney disease patients. World J Nephrol 2013; 2: 38-43.
  4. Li H, Feng SJ, Su LL, Wang W, Zhang XD, Wang SX. Serum hepcidin predicts uremic accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Chin Med J 2015; 128: 1351- 7. Van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2013; 28: 3062-71.
  5. Kali A, Yayar O, Erdogan B, Eser B, Buyukbakkal M, Ercan Z, et al. Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients? Hemodial Int 2016; 20: 191-7.
  6. Ulu SM, Yuksel S, Altuntas A, Kacar E, Ahsen A, Altug A, et al. Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients. Int Urol Nephrol 2014; 46: 2409-14
  7. Valenti L, Maloberti A, Signorini S, Milano M, Cesana F, Cappellini F, et al. Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension. PLoS One 2015; 10: e0134635. Pechlaner R, Kiechl S, Mayr M, Santer P, Weger S, Haschka D, et al. Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population. Clin Chem Lab Med 2016; 54: 151-61.
  8. Habib A, Polavarapu R, Karmali V, Guo L, Van Dam R, Cheng Q, et al. Hepcidin-ferroportin axis controls toll-like receptor 4 dependent macrophage inflammatory responses in human atherosclerotic plaques. Atherosclerosis 2015; 241: 692-700.
  9. Galesloot TE, Holewijn S, Kiemeney LA, de Graaf J, Vermeulen SH, Swinkels DW. Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population. Arterioscler